{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:22:18Z","timestamp":1772788938414,"version":"3.50.1"},"reference-count":21,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2023.2290386","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T02:51:09Z","timestamp":1701658269000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of clinical and economic impact\u202fof rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States"],"prefix":"10.1080","volume":"27","author":[{"given":"Anshul","family":"Shah","sequence":"first","affiliation":[{"name":"Evidera","place":["Mumbai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Dabbous","sequence":"additional","affiliation":[{"name":"Evidera Inc","place":["Bethesda, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surbhi","family":"Shah","sequence":"additional","affiliation":[{"name":"Evidera Inc","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Ashton","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs LLC","place":["Titusville, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Kharat","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs LLC","place":["Titusville, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.05.033"},{"key":"e_1_3_7_3_1","volume-title":"Peripheral arterial disease","author":"Zemaitis MR","year":"2022","unstructured":"Zemaitis MR, Boll JM, Dreyer MA. Peripheral arterial disease. Treasure Island (FL): StatPearls; 2022."},{"key":"e_1_3_7_4_1","unstructured":"Centers for Disease and Control (CDC). Peripheral Arterial Disease (PAD) December 19. 2022. https:\/\/www.cdc.gov\/heartdisease\/PAD.htm."},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0003319719896477"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.775247"},{"issue":"1","key":"e_1_3_7_8_1","article-title":"The high cost of peripheral artery disease and critical limb ischemia","volume":"1","author":"Yost ML.","year":"2021","unstructured":"Yost ML. The high cost of peripheral artery disease and critical limb ischemia. J Arterial Venous Lymphatic Interv. 2021;1(1)","journal-title":"J Arterial Venous Lymphatic Interv"},{"key":"e_1_3_7_9_1","volume-title":"The real cost of peripheral artery disease","author":"Yost ML.","year":"2011","unstructured":"Yost ML. The real cost of peripheral artery disease. Atlanta (GA): The Sage Group; 2011."},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.03.022"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2021.02.025"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.312142"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000052"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32409-1"},{"issue":"5","key":"e_1_3_7_16_1","first-page":"184","article-title":"Economic implications of preventing major cardiovascular and limb events with rivaroxaban plus aspirin in patients with coronary or peripheral artery disease in the United States","volume":"13","author":"Hernandez L","year":"2020","unstructured":"Hernandez L, Shah A, Zhao Q, et\u00a0al. Economic implications of preventing major cardiovascular and limb events with rivaroxaban plus aspirin in patients with coronary or peripheral artery disease in the United States. Am Health Drug Benefits. 2020;13(5):184\u2013190.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.079"},{"key":"e_1_3_7_18_1","unstructured":"IBM Micromedex\u00ae. RED BOOK\u00ae. 2022. https:\/\/www.ibm.com\/watson-health\/about\/micromedex."},{"key":"e_1_3_7_19_1","unstructured":"US Bureau of Labor Statistics. Consumer price index. January 2023 CPI weight update Washington DC. 2022. https:\/\/www.bls.gov\/cpi\/."},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0426-8"},{"key":"e_1_3_7_21_1","article-title":"Additive therapies for cardiovascular disease: effectiveness and value","author":"Ollendorf D","year":"2019","unstructured":"Ollendorf D, McQueen R, Campbell J, et\u00a0al. Additive therapies for cardiovascular disease: effectiveness and value. ICER. 2019.","journal-title":"ICER"},{"key":"e_1_3_7_22_1","article-title":"New developments in antiplatelet therapies for patients with peripheral artery disease","volume":"22","author":"Banerjee S.","year":"2016","unstructured":"Banerjee S. New developments in antiplatelet therapies for patients with peripheral artery disease. Am Coll Cardiol. 2016;22.","journal-title":"Am Coll Cardiol"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2290386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:40:36Z","timestamp":1772779236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2290386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2290386"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2290386","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}